These beneficial effects could be partially reversed by co-administration of the GLP-1R antagonist exendin (939)
Participants self-reported general dietary habits, including changes in food preferences since the start of GLP-1RA therapy
A resazurin solution (0.01 mg/ml) was added 4 h prior to the measurement
March 3, 2026 At a Glance Vivani Medical is developing a GLP-1 implant aimed at tackling challenges associated with other drug delivery forms
Effgem, Virginia, Canal, Cludia Patrocnio Pedroza, Missawa, Daniela Dadalto Ambrozine, & Rossetti, Claudia Broetto
Constipation ranks among the top three complaints from GLP-1 medication users, affecting up to 24% of patients in clinical trials